SCHEMBL4024150

SCHEMBL4024150

Fc1cccc(-c2cn3nc(Cl)ccc3n2)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F2RL3 Q96RI0 2/20 0.48
MAPT P10636 2/20 0.45
TP53 P04637 1/20 0.45
PDE10A Q9Y233 1/20 0.42
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
FYN P06241 3/20 0.40
TLR8 Q9NR97 1/20 0.40
ALDH1A3 P47895 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
IDO1 P14902 1/20 0.38
EGLN2 Q96KS0 1/20 0.38
AHR P35869 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4099914 0.87 DRD2 (0.42) F2RL3MAPTTP53KDM4EDRD2
SCHEMBL13750554 0.83 F2RL3 (0.51) F2RL3MAPTTP53PDE10AKDM4E
SCHEMBL1395044 0.82 DRD2 (0.49) F2RL3MAPTKDM4EDRD2DRD4
SCHEMBL3108835 0.82 NPC1 (0.54) MAPTTP53PDE10AKDM4EMEN1
SCHEMBL13731002 0.80 F2RL3 (0.48) F2RL3MAPTTP53PDE10AKDM4E
SCHEMBL12926168 0.80 CSNK1D (0.38) F2RL3MAPTTP53KDM4EDRD2
SCHEMBL44397 0.80 ALDH1A3 (0.53) PDE10AALDH1A3NPC1RAB9AIDO1
SCHEMBL1746565 0.75 DYRK3 (0.52) PDE10AFYNNPC1RAB9A
SCHEMBL22614984 0.75 NPC1 (0.57) F2RL3MAPTTP53KDM4EMEN1
SCHEMBL23535563 0.74 DYRK1A (0.58) F2RL3PDE10AKDM4EFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203705-A1 Spiro Compounds As NPY Y5 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2009-08-13 US disclosed
US-20090203705-A1 Spiro Compounds As NPY Y5 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2009-08-13 US disclosed
US-20090203705-A1 Spiro Compounds As NPY Y5 Receptor Antagonists GLAXO GROUP LIMITED (GB) 2009-08-13 US disclosed
WO-2009095377-A1 SPIRO COMPOUNDS AS NPY Y5 RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2009-08-06 WO disclosed
WO-2009095377-A1 SPIRO COMPOUNDS AS NPY Y5 RECEPTOR ANTAGONISTS GLAXO GROUP LIMITED (GB) 2009-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203705-A1 Spiro Compounds As NPY Y5 Receptor Antagonists NPY4R, NPY1R, NPY5R F2RL3 449/4885MAPT 4668/4885TP53 4792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.